Physician profile
Keesha P Kaplan
NPI 1366758153
$11,102.99
in general payments reported to CMS, 2019-2025
31 companies · $3,160 in 2025
The $3,160 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,481 · 2022: $1,740 · 2023: $2,421 · 2024: $2,302 · 2025: $3,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,249 · Education: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,249.42 |
| Education | $632.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,271.15 | 2021-2025 | |
| Janssen Biotech, INC. | $1,476.13 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,019.99 | 2022-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $802.08 | 2021-2025 | |
| Dermavant Sciences, INC. | $776.97 | 2023-2024 | Vtama |
| Genzyme Corporation | $771.41 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $592.35 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $566.99 | 2022-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $473.58 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.88 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $350.21 | 2021-2025 | Aklief, Nemluvio, Oracea |
| Merz North America, INC. | $231.72 | 2021-2022 | |
| Lilly USA, LLC | $225.58 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Arcutis Biotherapeutics, INC. | $201.19 | 2023-2025 | Zoryve |
| Organon LLC | $150.08 | 2024-2025 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $115.12 | 2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $108.86 | 2021-2025 | Dupixent |
| Incyte Corporation | $98.28 | 2023-2025 | Opzelura |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Vyne Pharmaceuticals INC. | $54.75 | 2021 | |
| Glaxosmithkline, LLC. | $52.93 | 2023 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $51.83 | 2025 | |
| Krystal Biotech INC | $47.36 | 2023-2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $41.89 | 2023-2025 | Ycanth |
| Botanix Sb INC | $34.50 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $30.35 | 2024 | Xtrac |
| Amgen INC. | $27.45 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $22.69 | 2025 | Sylvant |
| Acella Pharmaceuticals, LLC | $18.96 | 2025 | NP Thyroid 60 |
| Blueprint Medicines Corporation | $18.82 | 2023 | |
| Dermira, INC. | $17.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keesha Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.